SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Berkshire James G. | See Remarks | 2026-09-02 | Option exercise | 5381 | $709K |
| Berkshire James G. | See Remarks | 2026-09-02 | Open-market sell | 2668 | $697K |
| Berkshire James G. | See Remarks | 2026-09-02 | D | 2713 | $710K |
| STAUB W RICHARD | See Remarks | 2026-08-03 | Open-market sell | 5500 | $1.3M |
| Patel Bhavik | See Remarks | 2026-07-31 | Open-market sell | 1855 | $436K |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | Option exercise | 156206 | $12.2M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | Open-market sell | 4465 | $1.1M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | Open-market sell | 4584 | $1.1M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | Open-market sell | 44039 | $10.8M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | Open-market sell | 53191 | $13.0M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | D | 47858 | $11.7M |
| BOUSBIB ARI | See Remarks, Director | 2026-07-29 | D | 2069 | $511K |
| Cherofsky Keriann | See Remarks | 2026-07-29 | Open-market sell | 558 | $137K |
| Sherbet Eric | See Remarks | 2026-07-29 | Open-market sell | 5000 | $1.2M |
| Burt Carol | Director | 2026-04-23 | Grant/award | 1571 | $0 |
| DANHAKL JOHN G | Director | 2026-04-23 | Grant/award | 1571 | $0 |
| GOGGINS COLLEEN A | Director | 2026-04-23 | Grant/award | 1571 | $0 |
| LEONARD JOHN M | Director | 2026-04-23 | Grant/award | 1571 | $0 |
| Fedock Michael J. | See Remarks | 2026-02-13 | Tax withholding | 123 | $21K |
| Haas Bernd | See Remarks | 2026-02-13 | Tax withholding | 20 | $3K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
A broad sweep of risk-factor removals signals a materially simplified risk profile, most likely driven by the exit or divestiture of the R&D Solutions and Contract Sales & Medical Solutions business lines, which eliminated clinical trial liability, product liability, contract underpricing, and client conflict-of-interest exposures in one move. Debt structure risk also eased substantially, with both covenant and restrictive-covenant disclosures removed, pointing to a cleaner balance sheet. The sole deterioration — a new AI-enhanced cyberattack disclosure — is a real but contained escalation that does not offset the breadth of risk reduction.
0 company-specific · 11 eased/removed · 1 common-mode
Removal of IP infringement risk disclosure signals reduced exposure to costly litigation, injunctions, and indemnification claims that previously posed material adverse impact.
We may be subject to claims by others that we are infringing on their intellectual property rights. Third parties may assert claims that we or our clients infringe their intellectual property rights…
Removal of material operational risk regarding contract underpricing, cost overruns, and change order delays in R&D Solutions business. Suggests improved pricing discipline or reduced exposure.
Our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders. Most of…
Removal of Phase I clinical trial liability risk suggests company exited or substantially reduced this business line, materially easing operational and legal exposure.
Some of our services involve direct interaction with clinical trial subjects or volunteers and subcontracting into a network of Phase I clinical facilities, which could create potential liability…
Removal of debt covenant and leverage risk disclosure. Company no longer discloses potential for additional indebtedness under credit agreement loopholes, suggesting improved financial position or reduced leverage concerns.
Despite our level of indebtedness, we are able to incur more debt and undertake additional obligations. Incurring such debt or undertaking such additional obligations could further exacerbate the…
Removal of substantial clinical trial liability risk disclosure, including patient injury claims, investigator fraud, and regulatory compliance exposure. Suggests material reduction in R&D Solutions business risk or exit.
Our Research & Development Solutions business could subject us to potential liability that may adversely affect our results of operations and financial condition. Our Research & Development Solutions…
Removal of material product liability risk for Contract Sales & Medical Solutions business. Suggests business exit, divestiture, or material risk mitigation.
Our Contract Sales & Medical Solutions business could result in liability to us if a drug causes harm to a patient. While we are generally indemnified and insured against such risks, we may still…
Removal of material client conflict-of-interest risk. Company no longer discloses competitive client relationship constraints as a going concern, suggesting risk resolved or mitigated.
Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services, which may…
Removal of goodwill impairment risk disclosure suggests prior acquisition concerns resolved or assets written down. Material risk reduction for investors.
Our results of operations may be adversely affected if we fail to realize the full value of our goodwill and acquired intangible assets. We assess the realizability of our goodwill annually and…
Removal of material risk factor on biopharmaceutical industry outsourcing trends, R&D spending, and customer concentration. Suggests improved market conditions or reduced exposure.
Outsourcing trends in the biopharmaceutical industry and changes in aggregate spending and research and development budgets could adversely affect our operating results and growth rate. Economic…
Removal of material revenue risk from generic drug competition affecting R&D client spending. Suggests improved competitive position or changed business model reducing exposure.
Our Research & Development Solutions clients face intense competition from lower cost generic products, which may lower the amount that they spend on our services. Our Research & Development…
Removal of restrictive covenant disclosure suggests debt refinancing or payoff eliminated material operational constraints on acquisitions, dividends, asset sales, and financing flexibility.
Restrictive covenants in our other indebtedness may limit our flexibility in our current and future operations, particularly our ability to respond to changes in our business or to pursue our…
New disclosure of AI-supported cyberattacks as an emerging threat escalates the sophistication and severity of cyber risk beyond prior year's general language.
Security breaches and unauthorized use of our IT systems and information, or the IT systems or information in the possession of our vendors, could expose us, our clients, our data suppliers or others…
IQVIA's subsidiary entered into a purchase agreement to issue $2,000,000,000 in senior notes due 2034 bearing interest at 6.375% per annum, with closing expected September 23, 2026. This creates a new direct financial obligation and is a material capital event for the registrant, fitting squarely within the debt_issuance category. The proceeds are earmarked for redemption of existing notes and repayment of revolving credit facility indebtedness.
View raw filing on EDGAR →IQVIA disclosed its second-quarter 2026 financial results via press release on July 28, 2026, reporting revenue of $4,368 million (up 8.7% YoY), GAAP net income of $256 million, and adjusted diluted EPS of $3.15 (up 12.1% YoY). The company also raised full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted EPS. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →IQVIA completed issuance of €950 million in senior notes on June 11, 2026, pursuant to a definitive indenture agreement. The proceeds are being used to refinance existing indebtedness, representing a material capital structure and debt financing event.
View raw filing on EDGAR →IQVIA announced a €950 million senior notes offering due 2033 at 4.625% per annum, with expected closing on June 11, 2026. While this is a material financing event affecting the company's capital structure and liquidity, it does not fit neatly into the standard 8-K taxonomy categories (not M&A, not a dilutive equity issuance, not a covenant breach or going-concern disclosure). This is a significant debt issuance that would affect investor assessment of the registrant's financial position and leverage.
View raw filing on EDGAR →The disclosure announces a €950 million senior notes offering by IQVIA Inc. (wholly owned subsidiary) and refinancing of existing indebtedness. While this is a material financing event affecting the company's capital structure and debt profile, it is not a traditional M&A activity (acquisition, disposition, merger, or change of control). The event is material to investors but does not fit cleanly into the taxonomy; it is best classified as "other_material" rather than forcing it into ma_activity.
View raw filing on EDGAR →